Moffitt logo

COVID-19 Safety Precautions: Find the Latest Visitor and Mask Policies. Learn More

Clinical Trials Search

Search Results:

Showing of 50

CLINICAL TRIAL 21219

Predicting Progression of Developing Myeloma in a High-Risk Screened Population

Cancer Type: Malignant Hematology

View Trial Details

CLINICAL TRIAL 20253

Open Label, Multi-Center, Phase 1b Clinical Trial to Evaluate the Safety and Efficacy of Autologous CAR-BCMA T cells (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma

Cancer Type: Multiple Myeloma

View Trial Details

CLINICAL TRIAL 20753

An Open-Label Phase I, Multi-Center Study to Determine the Recommended Dose of the Chimeric Antigen Receptor T-cell Treatment CYAD-211 After a Non-Myeloablative Preconditioning Chemotherapy in Multiple Myeloma Patients with Relapsed or Refractory Disease (IMMUNICY-1)

Cancer Type: Multiple Myeloma

View Trial Details

CLINICAL TRIAL 20038

Phase I Dose-Escalation and Dose-Expansion Trial of a Novel Glutaminase Inhibitor (CB-839 HCl) in Combination with Carfilzomib and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma

Cancer Type: Malignant Hematology

View Trial Details

CLINICAL TRIAL 19722

A Phase 2, Multi-Cohort, Open-Label, Multicenter Study To Determine The Efficacy And Safety Of Bb2121 In Subjects With Relapsed And Refractory Multiple Myeloma And In Subjects With High-Risk Multiple Myeloma Having Progressed Within One Year Of Initial Treatment

Cancer Type: Malignant Hematology

View Trial Details

CLINICAL TRIAL 19428

A Phase 1/2, Multicenter, Dose-Escalation and Expansion Study of Combination Therapy with Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Subjects with Relapsed or Refractory Multiple Myeloma

Cancer Type: Malignant Hematology

View Trial Details

CLINICAL TRIAL 20281

MLN9708 (Ixazomib) and MLN4924 (Pevonedistat) in Relapsed/Refractory Multiple Myeloma Patients: A Phase 1b Trial

Cancer Type: Malignant Hematology

View Trial Details

CLINICAL TRIAL 20130

Phase II Study of Daratumumab Based Response Adapted Therapy for Older Adults with Newly Diagnosed Multiple Myeloma

Cancer Type: Malignant Hematology

View Trial Details

CLINICAL TRIAL 20361

A Phase 1, Open-Label, Multi-Center, Dose Escalation and Dose Expansion Study of NKTR-255 As A Single Agent In Relapsed Or Refractory Hematological Malignancies and In Combination With Daratumumab As A Salvage Regimen for Multiple Myeloma

Cancer Type: Malignant Hematology

View Trial Details

CLINICAL TRIAL 20413

Phase III Study Of Daratumumab/Rhuph20 (Nsc- 810307) + Lenalidomide Or Lenalidomide As Post-Autologous Stem Cell Transplant Maintenance Therapy In Patients With Multiple Myeloma (MM) Using Minimal Residual Disease To Direct Therapy Duration (DRAMMATIC STUDY)

Cancer Type: Malignant Hematology

View Trial Details

CLINICAL TRIAL 20156

Mindfulness in AYA Patients Undergoing Hematopoietic Stem Cell Transplantation: A Pilot Proposal

Cancer Type: Multiple Myeloma

View Trial Details

CLINICAL TRIAL 20615

A Phase 1 Open-Label, Multi-Center First in Human Study of TnMUC1-Targeted Genetically-Modified Chimeric Antigen Receptor T Cells in Patients with Advanced TnMUC1-Positive Solid Tumors and Multiple Myeloma

Cancer Type: Thoracic

View Trial Details

CLINICAL TRIAL 18926

The National Myelodysplastic Syndromes (MDS) Study

Cancer Type: Malignant Hematology

View Trial Details
;